Objective: To study the feasibility of modified urinary nucleosides metabolic profiling on lung cancer diagnoses.
Methods: The modified urinary nucleosides metabolic profiling from 42 normal adults and 80 patients with lung cancer were determined by a coupled-column high performance liquid chromatography system. Partial least squares-discriminant analysis (PLS-DA) models were used to class differentiation between the lung cancer patients and controls and to discover potential biomarkers.
Result: The PLS-DA model results showed that there was a clear differentiation between normal adults and lung cancers patients, with the value of prediction (Q2) equals to 0.744.
Conclusion: Modified urinary nucleosides metabolic profiling method is useful for lung cancer diagnoses.